



(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/079144

(22) International Filing Date:

02 November 2022 (02.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/275,356 03 November 2021 (03.11.2021) US

(71) Applicant: **JANSSEN BIOTECH, INC.** [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(72) Inventors: **GOLDBERG, Jenna D.**; 920 US Highway
202 South, Raritan, New Jersey 08869 (US). **WANG LIN,
Shun Xin**; 1400 McKean Rd., Spring House, Pennsylva-
nia 19477 (US). **PRIOR, Thomas J.**; 1400 McKean Rd.,
Spring House, Pennsylvania 19477 (US). **VERONA, Ralu-
ca**; 1400 McKean Rd., Spring House, Pennsylvania 19477
(US). **WEISS, Brendan**; 1400 McKean Rd., Spring House,
Pennsylvania 19477 (US).


(74) Agent: **BODLE, Christopher R.**; TROUTMAN PEPPER
HAMILTON SANDERS LLP, 501 Grant Street, Suite
300, Union Trust Building, Pittsburgh, Pennsylvania 15219
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTI-BODIES

FIG. 1



Abbreviations: RP2D=recommended Phase 2 dose.

(57) Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics. In particular, methods are disclosed of using a GPRC5DxCD3 bispecific antibody, an anti-CD38 antibody and/or pomalidomide to treat cancers.

[Continued on next page]

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*